US Stock MarketDetailed Quotes

XERS Xeris Pharmaceuticals

Watchlist
  • 2.040
  • -0.010-0.49%
Close Mar 27 16:00 ET
286.53MMarket Cap-4533P/E (TTM)

About Xeris Pharmaceuticals Company

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Company Profile

SymbolXERS
Company NameXeris Pharmaceuticals
Listing Date06/21/2018
Issue Price15.00
Founded2005
CEOMr. Paul R. Edick
MarketNASDAQ
Employees377
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1375 West Fulton Street,Suite 1300
CityChicago
ProvinceIllinois
CountryUnited States of America
Zip Code60607
Phone1-844-445-5704

Company Executives

  • Name
  • Position
  • Salary
  • Paul R. Edick
  • Chairman of the Board and Chief Executive Officer
  • 2.81M
  • John Shannon
  • President and Chief Operating Officer
  • 1.53M
  • Beth P. Hecht
  • Chief Legal Officer and Corporate Secretary
  • 1.27M
  • Dr. Steven Prestrelski, PhD
  • Chief Scientific Officer
  • --
  • Steven M. Pieper
  • Chief Financial Officer and Principal Accounting officer
  • --
  • Dr. Ken Johnson
  • Senior Vice President, Global Development and Medical Affairs
  • --
  • Ricki Louise Fairley
  • Director
  • --
  • Dr. Jeffrey W. Sherman, F.A.C.P.,M.D.
  • Independent Director
  • 119.74K
  • John H. Johnson
  • Independent Director
  • 112.24K
  • Marla S. Persky
  • Independent Director
  • 127.24K
  • John P. Schmid
  • Lead Independent Director
  • 162.24K
  • Dr. Garheng Kong, M.D.,PhD
  • Independent Director
  • 117.24K
  • Dr. B. J. Bormann, PhD
  • Independent Director
  • 127.24K
  • Dawn Halkuff
  • Independent Director
  • 119.74K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg